Dynavax Technologies (NASDAQ:DVAX - Get Free Report) will likely be releasing its Q4 2024 earnings data after the market closes on Thursday, February 20th. Analysts expect Dynavax Technologies to post earnings of $0.05 per share and revenue of $72.70 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. The firm had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Dynavax Technologies Stock Performance
Dynavax Technologies stock remained flat at $13.33 during midday trading on Friday. 2,869,831 shares of the company traded hands, compared to its average volume of 1,660,510. Dynavax Technologies has a one year low of $9.74 and a one year high of $14.05. The stock has a market capitalization of $1.75 billion, a P/E ratio of 74.06 and a beta of 1.32. The stock has a 50-day moving average of $12.82 and a two-hundred day moving average of $12.04. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on DVAX shares. HC Wainwright restated a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price target for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday.
Check Out Our Latest Research Report on DVAX
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
